If you have been told your insurance does not cover Zepbound, your three real options in 2026 are not "give up," "pay $1,086 a month at the pharmacy," and "try to game the system." They are three legitimate, fully legal pathways to brand-name or pharmaceutical-grade tirzepatide, each at dramatically lower cost than the retail pharmacy quote, each with a different trade-off, and each available in all 50 states. We call them loopholes because they bypass the insurance maze entirely. They are not actually loopholes. They are how the manufacturer and the licensed compounding industry have responded to a coverage gap they know costs them and you sales every day.
This is the practical guide. Three routes, side by side, with what each costs, what you get, and how to enroll.
Route A — LillyDirect Zepbound vials
What it is: Eli Lilly directly sells single-dose vials of Zepbound — the same brand-name FDA-approved tirzepatide as the pen — through their LillyDirect platform. Vials ship to your home from Lilly's distribution partner. No insurance. No PBM. No pharmacy markup. Flat national pricing.
What it costs:
| Dose | Format | Monthly cost |
|---|---|---|
| 2.5 mg / week (titration) | 4 single-dose vials | $349 |
| 5 mg / week (common maintenance) | 4 single-dose vials | $499 |
| 7.5 mg / week | 4 single-dose vials | $599 |
| 10 mg / week (max via LillyDirect) | 4 single-dose vials | $649 |
What you give up: The pen format. LillyDirect ships single-dose vials, which means you draw the dose into a syringe yourself once a week. This is functionally identical to how every diabetes patient has used insulin for fifty years and is straightforward once you have done it twice — but if you are needle-averse, this is the bigger psychological adjustment of the route.
What you get: Brand-name FDA-approved Zepbound. Same molecule as the pen. Same Eli Lilly quality assurance. Same FDA regulatory protection. Same adverse-event reporting and recall pathway. As of 2026 the highest dose available via LillyDirect is 10 mg/week — patients titrating beyond that need to convert to pen via insurance or another route.
How to enroll: Telehealth visit through the LillyDirect platform to obtain a Zepbound prescription, or bring your own existing Zepbound prescription. Eligibility is based on having an obesity diagnosis (BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity). The platform handles fulfillment and reorders.
LillyDirect is a deliberate workaround for Lilly's own commercial-coverage problem. They knew commercial insurance would not consistently cover Zepbound for obesity. Rather than lose those patients to compounded competitors, they built a direct-to-patient channel at half the WAC. It is a legitimate manufacturer self-pay program that is doing real volume in 2026 — not a backdoor or a gray-area route.
Route B — Brand prescription via direct-pay telehealth
What it is: A direct-pay telehealth visit (through a marketplace like Sesame Care or a similar model) to obtain a prescription for brand-name Wegovy, Zepbound, Mounjaro, or Ozempic, which the patient then fills at retail pharmacy or via the manufacturer's self-pay program. This is essentially Route A with a different prescriber-acquisition path, and it is useful if you do not already have a prescriber willing to write for these medications.
What it costs: Two-part pricing. (1) The telehealth visit is typically $79 to $199 as a one-time or annual fee. (2) The medication itself is then filled at whatever the cash channel costs — LillyDirect Zepbound at $349-$649, NovoCare Direct Wegovy at approximately $499, or retail pharmacy with savings card if applicable.
What you give up: Compared to a primary-care prescriber relationship, you give up the continuity of care and the integrated chart. The telehealth visit is transactional — get the prescription, fill it, schedule follow-ups as needed.
What you get: A legitimate prescription for the brand-name medication you actually want. This is the right route for patients whose primary-care physician is hesitant or unwilling to prescribe GLP-1s, or for patients without a current PCP relationship. Sesame Care specifically prescribes brand-name FDA-approved medications — they do not deal in compounded products.
How to enroll: Book a visit with a prescriber on Sesame Care or a similar direct-pay marketplace. Have your medical history (or willingness to discuss it), your BMI, and any relevant lab results ready. The visit takes 15-30 minutes; if approved, the prescription is sent to your pharmacy of choice or to a manufacturer self-pay program.
Sesame Care and similar direct-pay marketplaces work with prescribers who write for FDA-approved brand-name medications. They do not facilitate compounded prescriptions. If your goal is to get the cheapest possible cost via the compounded route, Route B is not the right path — you want Route C. If your goal is to get a brand-name prescription without dealing with insurance, Route B is the cleanest way to do it.
Route C — Compounded tirzepatide via licensed telehealth
What it is: A telehealth provider partners with a licensed 503A or 503B compounding pharmacy to produce tirzepatide formulations under valid individual prescriptions. The medication is not the FDA-approved Zepbound or Mounjaro; it is a compounded preparation containing tirzepatide as the active ingredient, often combined with B12, glycine, or other personalization elements that bring the formulation under the 503A personalized-prescription pathway.
What it costs: $179 to $399 per month, dose-dependent and provider-dependent.
| Tier | Monthly cost (5 mg) | Examples |
|---|---|---|
| Aggressive value | $179 – $199 | Gala GLP-1, MadeMed |
| Mid-market | $229 – $279 | Yucca Health, Care Bare Rx, Sprout, MEDVi |
| Premium compounded | $299 – $399 | Embody, Wellorithm |
What you give up: FDA approval as a finished drug. Compounded medications are not FDA-approved; they are dispensed under valid prescription from licensed compounding pharmacies. This means the FDA's quality-and-oversight framework that applies to brand Zepbound does not apply in the same way. Reputable compounding pharmacies (especially 503B-registered outsourcing facilities) carry rigorous in-house quality programs and FDA inspection oversight, but the regulatory profile is different from FDA-approved brand product.
What you get: Tirzepatide — the same molecule, dispensed through a different regulatory pathway, at a substantially lower price. Most patients on legitimate compounded telehealth in 2026 receive a sterile, lab-tested, refrigerated product that performs clinically the same as the brand. The variability between providers is real, which is why provider vetting matters.
How to enroll: Telehealth intake (typically a brief health questionnaire and a video or asynchronous visit). If approved, the provider's pharmacy partner ships your medication monthly. Quality-of-experience varies enormously by provider — see our companion piece The Cheapest GLP-1 in 2026 for a tier-by-tier comparison.
Side-by-side comparison
| Attribute | Route A (LillyDirect) | Route B (Sesame brand) | Route C (Compounded) |
|---|---|---|---|
| Monthly cost | $349 – $649 | $80-$200 visit + medication cost | $179 – $399 |
| Brand-name FDA-approved? | Yes | Yes | No (compounded) |
| Format | Single-dose vial | Pen or vial (per pharmacy) | Multi-dose vial typically |
| Insurance involved? | No | No | No |
| National availability | All 50 states | All 50 states | Most states (varies by provider) |
| Maximum dose | 10 mg/week | 15 mg/week (full pen line) | 10-15 mg/week (provider varies) |
| Best for | Brand fans on a budget | Patients without a PCP | Lowest-cost legitimate route |
Which route fits which patient
Pick Route A (LillyDirect) if: You strongly prefer brand-name FDA-approved medication, you can absorb $499/month at the typical maintenance dose, you are comfortable drawing from a vial, and your dose stays at 10 mg/week or below. This is the most-recommended route for brand-loyal cash-pay patients in 2026.
Pick Route B (Sesame Care or similar) if: You want a brand-name prescription and you do not currently have a prescriber willing to write for tirzepatide. You are essentially using Sesame to get the prescription, then filling via Route A or retail. Most patients who go this route end up at the same destination as Route A patients but with an added step.
Pick Route C (compounded telehealth) if: You are budget-prioritizing and comfortable with the regulatory profile of compounded medication from a vetted provider. This is the route that takes you from $1,086/month at retail pharmacy to $179/month, all-in. It requires more diligence in provider selection but is the lowest-cost legitimate path to tirzepatide in the United States.
You are not locked in. Many patients start on Route C (compounded) for affordability while titrating up, then switch to Route A (LillyDirect) once they reach maintenance dose and want the FDA-approved brand. Others do the reverse — start on brand for the regulatory comfort, switch to compounded once they are stable. The molecule is the same; you do not need to re-titrate when switching at the same dose.
Pseudo-routes to avoid
While there are three legitimate pathways, the GLP-1 market in 2026 also contains a number of pseudo-routes that look attractive but are not legitimate:
Imported tirzepatide from overseas pharmacies. Various online vendors offer tirzepatide shipped from outside the US. These products are not FDA-regulated, the supply chain is unverified, and the legal status of personal importation is murky at best. Quality is unpredictable. Avoid.
"Research-grade" or "not for human use" peptides. Some vendors sell tirzepatide labeled as research chemicals at cheap prices. These products are not pharmaceutical-grade, are not intended for human use, and have no quality assurance. Several documented cases of contaminated or under-dosed product. Avoid.
Asking your PCP to write Mounjaro for an off-label obesity indication. This is technically legal off-label prescribing but creates documentation problems and is increasingly caught and rejected by PBMs and pharmacies. Use the labeled drug for your labeled indication.
"Compounded" telehealth providers that will not identify their pharmacy partner. Reputable compounded providers tell you exactly which pharmacy fills your prescription, what their licensing is, and what is in your formulation. Providers who refuse to share that information are the ones to avoid.
The bottom line
If your insurance does not cover Zepbound, you are not stuck. Three legitimate, fully legal routes give you brand-name FDA-approved tirzepatide for $349-$649/month, brand-name with a different prescriber pathway, or compounded pharmaceutical-grade tirzepatide for $179-$399/month. Each fits a different patient. Each is dramatically cheaper than the $1,086 retail pharmacy cash quote that drives most of the bad-experience stories in the GLP-1 market. Pick the one that fits your priorities, vet your provider carefully if going compounded, and stop paying retail pharmacy cash prices for a drug that has cheaper legitimate routes available in every US zip code.
For the deeper provider-by-provider breakdown, see The Cheapest GLP-1 in 2026: We Compared 23 Telehealth Providers. For why the price gap exists in the first place, see Tirzepatide Math: Why a Vial Costs $179 and the Same Drug at the Pharmacy Costs $1,069.